Hyperamylinemia is associated with hyperinsulinemia in the glucose- tolerant, insulin-resistant offspring of two Mexican-American non-insulin- dependent diabetic parents

Giovanni Gulli, Luciano Rossetti, Ralph A Defronzo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Several investigations have presented evidence that amylin inhibits insulin secretion and induces insulin resistance both in vitro and in viva. However, basal and postmeal amylin concentrations proved similar in non- insulin-dependent diabetes mellitus (NIDDM) patients and controls. Since hyperglycemia may alter both amylin and insulin secretion, we examined basal and glucose-stimulated amylin secretion in eight glucose-tolerant, insulin- resistant Mexican-American subject with both parents affected with NIDDM (offspring) end correlated the findings with the insulin sensitivity data acquired by an insulin clamp. Eight offspring and eight Mexican-Americans without any family history of diabetes (controls) underwent measurement of fat free mass (3H2O dilution method), 180-minutes, 75-g oral glucose tolerance test (OGTT), and 40-mU/m2, 180-minute euglycemic insulin clamp associated with 3H-glucose infusion and indirect calorimetry. Fasting amylin was significantly increased in offspring versus controls (11.5 ± 1.4 v 7.0 ± 0.8 pmol/L, P < .05). After glucose ingestion, both total (3,073 ± 257 v 1.870 ± 202 pmol · L-1 · min-1, P < .01) and incremental (1,075 ± 170 v 518 ± 124 pmol · L-1 · min-1, P < .05) areas under the curve (AUCs) of amylin concentration were significantly greater in offspring. The amylin to insulin molar ratio was similar in offspring and controls at all time points. Basal and postglucose insulin and C-peptide concentrations were significantly increased in the offspring. No correlation was found between fasting amylin, postglucose amylin AUC or IRUC, and any measured parameter of glucose metabolism during a euglycemic-hyperinsulinemic clamp (total glucose disposal, 7.21 ± 0.73 v 11.03 ± 0.54, P < 001; nonoxidative glucose disposal 3.17 ± 0.59 v 6.33 ± 0.56, P < .002; glucose oxidation 4.05 p 0.46 v 4.71 ± 0.21, P = NS; hepatic glucose production, 0.29 ± 0.16 v 0.01 ± 0.11, P = NS; all mg · min-1 · kg-1 fat-free mass, offspring v controls. In conclusion, these data do not support a causal role for amylin in the genesis of insulin resistance in NIDDM.

Original languageEnglish (US)
Pages (from-to)1157-1161
Number of pages5
JournalMetabolism: Clinical and Experimental
Volume46
Issue number10
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Islet Amyloid Polypeptide
Hyperinsulinism
Parents
Insulin
Glucose
Type 2 Diabetes Mellitus
Insulin Resistance
Glucose Clamp Technique
Area Under Curve
Fasting
Fats
Indirect Calorimetry
C-Peptide
Glucose Tolerance Test
Hyperglycemia
Eating

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{17b4bcef49a342c3938bf166e67dbec3,
title = "Hyperamylinemia is associated with hyperinsulinemia in the glucose- tolerant, insulin-resistant offspring of two Mexican-American non-insulin- dependent diabetic parents",
abstract = "Several investigations have presented evidence that amylin inhibits insulin secretion and induces insulin resistance both in vitro and in viva. However, basal and postmeal amylin concentrations proved similar in non- insulin-dependent diabetes mellitus (NIDDM) patients and controls. Since hyperglycemia may alter both amylin and insulin secretion, we examined basal and glucose-stimulated amylin secretion in eight glucose-tolerant, insulin- resistant Mexican-American subject with both parents affected with NIDDM (offspring) end correlated the findings with the insulin sensitivity data acquired by an insulin clamp. Eight offspring and eight Mexican-Americans without any family history of diabetes (controls) underwent measurement of fat free mass (3H2O dilution method), 180-minutes, 75-g oral glucose tolerance test (OGTT), and 40-mU/m2, 180-minute euglycemic insulin clamp associated with 3H-glucose infusion and indirect calorimetry. Fasting amylin was significantly increased in offspring versus controls (11.5 ± 1.4 v 7.0 ± 0.8 pmol/L, P < .05). After glucose ingestion, both total (3,073 ± 257 v 1.870 ± 202 pmol · L-1 · min-1, P < .01) and incremental (1,075 ± 170 v 518 ± 124 pmol · L-1 · min-1, P < .05) areas under the curve (AUCs) of amylin concentration were significantly greater in offspring. The amylin to insulin molar ratio was similar in offspring and controls at all time points. Basal and postglucose insulin and C-peptide concentrations were significantly increased in the offspring. No correlation was found between fasting amylin, postglucose amylin AUC or IRUC, and any measured parameter of glucose metabolism during a euglycemic-hyperinsulinemic clamp (total glucose disposal, 7.21 ± 0.73 v 11.03 ± 0.54, P < 001; nonoxidative glucose disposal 3.17 ± 0.59 v 6.33 ± 0.56, P < .002; glucose oxidation 4.05 p 0.46 v 4.71 ± 0.21, P = NS; hepatic glucose production, 0.29 ± 0.16 v 0.01 ± 0.11, P = NS; all mg · min-1 · kg-1 fat-free mass, offspring v controls. In conclusion, these data do not support a causal role for amylin in the genesis of insulin resistance in NIDDM.",
author = "Giovanni Gulli and Luciano Rossetti and Defronzo, {Ralph A}",
year = "1997",
doi = "10.1016/S0026-0495(97)90209-2",
language = "English (US)",
volume = "46",
pages = "1157--1161",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Hyperamylinemia is associated with hyperinsulinemia in the glucose- tolerant, insulin-resistant offspring of two Mexican-American non-insulin- dependent diabetic parents

AU - Gulli, Giovanni

AU - Rossetti, Luciano

AU - Defronzo, Ralph A

PY - 1997

Y1 - 1997

N2 - Several investigations have presented evidence that amylin inhibits insulin secretion and induces insulin resistance both in vitro and in viva. However, basal and postmeal amylin concentrations proved similar in non- insulin-dependent diabetes mellitus (NIDDM) patients and controls. Since hyperglycemia may alter both amylin and insulin secretion, we examined basal and glucose-stimulated amylin secretion in eight glucose-tolerant, insulin- resistant Mexican-American subject with both parents affected with NIDDM (offspring) end correlated the findings with the insulin sensitivity data acquired by an insulin clamp. Eight offspring and eight Mexican-Americans without any family history of diabetes (controls) underwent measurement of fat free mass (3H2O dilution method), 180-minutes, 75-g oral glucose tolerance test (OGTT), and 40-mU/m2, 180-minute euglycemic insulin clamp associated with 3H-glucose infusion and indirect calorimetry. Fasting amylin was significantly increased in offspring versus controls (11.5 ± 1.4 v 7.0 ± 0.8 pmol/L, P < .05). After glucose ingestion, both total (3,073 ± 257 v 1.870 ± 202 pmol · L-1 · min-1, P < .01) and incremental (1,075 ± 170 v 518 ± 124 pmol · L-1 · min-1, P < .05) areas under the curve (AUCs) of amylin concentration were significantly greater in offspring. The amylin to insulin molar ratio was similar in offspring and controls at all time points. Basal and postglucose insulin and C-peptide concentrations were significantly increased in the offspring. No correlation was found between fasting amylin, postglucose amylin AUC or IRUC, and any measured parameter of glucose metabolism during a euglycemic-hyperinsulinemic clamp (total glucose disposal, 7.21 ± 0.73 v 11.03 ± 0.54, P < 001; nonoxidative glucose disposal 3.17 ± 0.59 v 6.33 ± 0.56, P < .002; glucose oxidation 4.05 p 0.46 v 4.71 ± 0.21, P = NS; hepatic glucose production, 0.29 ± 0.16 v 0.01 ± 0.11, P = NS; all mg · min-1 · kg-1 fat-free mass, offspring v controls. In conclusion, these data do not support a causal role for amylin in the genesis of insulin resistance in NIDDM.

AB - Several investigations have presented evidence that amylin inhibits insulin secretion and induces insulin resistance both in vitro and in viva. However, basal and postmeal amylin concentrations proved similar in non- insulin-dependent diabetes mellitus (NIDDM) patients and controls. Since hyperglycemia may alter both amylin and insulin secretion, we examined basal and glucose-stimulated amylin secretion in eight glucose-tolerant, insulin- resistant Mexican-American subject with both parents affected with NIDDM (offspring) end correlated the findings with the insulin sensitivity data acquired by an insulin clamp. Eight offspring and eight Mexican-Americans without any family history of diabetes (controls) underwent measurement of fat free mass (3H2O dilution method), 180-minutes, 75-g oral glucose tolerance test (OGTT), and 40-mU/m2, 180-minute euglycemic insulin clamp associated with 3H-glucose infusion and indirect calorimetry. Fasting amylin was significantly increased in offspring versus controls (11.5 ± 1.4 v 7.0 ± 0.8 pmol/L, P < .05). After glucose ingestion, both total (3,073 ± 257 v 1.870 ± 202 pmol · L-1 · min-1, P < .01) and incremental (1,075 ± 170 v 518 ± 124 pmol · L-1 · min-1, P < .05) areas under the curve (AUCs) of amylin concentration were significantly greater in offspring. The amylin to insulin molar ratio was similar in offspring and controls at all time points. Basal and postglucose insulin and C-peptide concentrations were significantly increased in the offspring. No correlation was found between fasting amylin, postglucose amylin AUC or IRUC, and any measured parameter of glucose metabolism during a euglycemic-hyperinsulinemic clamp (total glucose disposal, 7.21 ± 0.73 v 11.03 ± 0.54, P < 001; nonoxidative glucose disposal 3.17 ± 0.59 v 6.33 ± 0.56, P < .002; glucose oxidation 4.05 p 0.46 v 4.71 ± 0.21, P = NS; hepatic glucose production, 0.29 ± 0.16 v 0.01 ± 0.11, P = NS; all mg · min-1 · kg-1 fat-free mass, offspring v controls. In conclusion, these data do not support a causal role for amylin in the genesis of insulin resistance in NIDDM.

UR - http://www.scopus.com/inward/record.url?scp=0030882286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030882286&partnerID=8YFLogxK

U2 - 10.1016/S0026-0495(97)90209-2

DO - 10.1016/S0026-0495(97)90209-2

M3 - Article

C2 - 9322799

AN - SCOPUS:0030882286

VL - 46

SP - 1157

EP - 1161

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 10

ER -